# BigHat Biosciences

> AI-guided antibody design platform (Milliner) for safer protein therapeutics.

## Why it is interesting

Tight ML–wet-lab loop compresses antibody optimization cycles — a16z-led A round with 8VC before Section 32-led scale-up.

## Profile

- **Stage:** series-b
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (Feb 2021): $19M led by a16z Bio + Health with 8VC participation (company press)
- Series B (Jul 2022): $75M led by Section 32; a16z and 8VC re-upped (BigHat Bio)
- Co-investors not in VCT directory: Section 32, AME Cloud Ventures, Amgen Ventures
- Source: https://www.bighatbio.com/news/bighat-biosciences-raises-19-million-in-series-a-funding-to-advance-antibody-design-and-development-for-safer-more-effective-treatments

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/8vc
- https://venturecapitaltracker.com/fund/gaingels

---
Source: https://venturecapitaltracker.com/startup/bighat-biosciences